{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:14:08Z","timestamp":1740140048083,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-022-02378-7","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T17:09:24Z","timestamp":1660928964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fixed Dose Combination Tablets of Aripiprazole and Divalproex Sodium: a Pilot Pharmacokinetic Study in Human Volunteers"],"prefix":"10.1208","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4161-0422","authenticated-orcid":false,"given":"Zia","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazal","family":"Subhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"2378_CR1","volume-title":"The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines","author":"Organization WH","year":"1992","unstructured":"Organization WH. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992."},{"key":"2378_CR2","volume-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","author":"Association AP","year":"2002","unstructured":"Association AP. Practice guideline for the treatment of patients with bipolar disorder (revision): American Psychiatric Pub; 2002."},{"issue":"8","key":"2378_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1745-7599.2006.00148.x","volume":"18","author":"K Miller","year":"2006","unstructured":"Miller K. Bipolar disorder: etiology, diagnosis, and management. J Am Acad Nurse Pract. 2006;18(8):368\u201373.","journal-title":"J Am Acad Nurse Pract"},{"key":"2378_CR4","volume-title":"Clinical guide to the diagnosis and treatment of mental disorders","author":"MB First","year":"2011","unstructured":"First MB, Tasman A. Clinical guide to the diagnosis and treatment of mental disorders: John Wiley & Sons; 2011."},{"issue":"1","key":"2378_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1176\/foc.1.1.64","volume":"1","author":"RM Hirschfeld","year":"2003","unstructured":"Hirschfeld RM, Bowden CL, Gitlin MJ, Keck PE, Perlis RH, Suppes T, et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Focus. 2003;1(1):64\u2013110.","journal-title":"Focus."},{"issue":"14","key":"2378_CR6","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1517\/14656566.2012.719876","volume":"13","author":"A de Bartolomeis","year":"2012","unstructured":"de Bartolomeis A, Perugi G. Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance. Expert Opin Pharmacother. 2012;13(14):2027\u201336.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"2378_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/cns.12017","volume":"18","author":"PA Geoffroy","year":"2012","unstructured":"Geoffroy PA, Etain B, Henry C, Bellivier F. Combination therapy for manic phases: a critical review of a common practice. CNS Neurosci Ther. 2012;18(12):957\u201364.","journal-title":"CNS Neurosci Ther"},{"key":"2378_CR8","volume-title":"American psychiatric association practice guideline for the treatment of patients with bipolar disorder","author":"Association AP","year":"2002","unstructured":"Association AP. American psychiatric association practice guideline for the treatment of patients with bipolar disorder: American Psychiatric Pub; 2002."},{"key":"2378_CR9","doi-asserted-by":"crossref","unstructured":"Suppes T, Vieta E, Liu S, Brecher M, Paulsson B, Investigators T. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatr. 2009.","DOI":"10.1176\/appi.ajp.2008.08020189"},{"issue":"1","key":"2378_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-7-40","volume":"7","author":"S Derry","year":"2007","unstructured":"Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry. 2007;7(1):1.","journal-title":"BMC Psychiatry"},{"issue":"7273","key":"2378_CR11","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","volume":"321","author":"J Geddes","year":"2000","unstructured":"Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371\u20136.","journal-title":"BMJ."},{"issue":"12","key":"2378_CR12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1080\/14740338.2020.1832990","volume":"19","author":"A Preda","year":"2020","unstructured":"Preda A, Shapiro BB. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opin Drug Saf. 2020;19(12):1529\u201338.","journal-title":"Expert Opin Drug Saf"},{"key":"2378_CR13","volume-title":"Gilman\u2019s the pharmacological basis of therapeutics 12th ed","author":"B Chabner","year":"2011","unstructured":"Chabner B, Goodman KB. Gilman\u2019s the pharmacological basis of therapeutics 12th ed. New York: McGraw-Hill. [Google Scholar]; 2011."},{"key":"2378_CR14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781585623860","volume-title":"The American psychiatric publishing textbook of psychopharmacology","author":"AF Schatzberg","year":"2009","unstructured":"Schatzberg AF, Nemeroff CB. The American psychiatric publishing textbook of psychopharmacology: American Psychiatric Pub; 2009."},{"key":"2378_CR15","doi-asserted-by":"crossref","unstructured":"Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatr. 1998.","DOI":"10.1176\/ajp.155.1.12"},{"issue":"1","key":"2378_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.ajp.161.1.3","volume":"161","author":"MS Bauer","year":"2004","unstructured":"Bauer MS, Mitchner L. What is a \u201cmood stabilizer\u201d? An evidence-based response. Am J Psychiatr. 2004;161(1):3\u201318.","journal-title":"Am J Psychiatr"},{"key":"2378_CR17","first-page":"33","volume":"27","author":"Z Ahmed","year":"2014","unstructured":"Ahmed Z, Subhan F, Shah MT, Farooq S. Effect of fasting on serum lithium levels: an experimental Study in animal models. Pak J Pharm Sci. 2014;27:33\u20137.","journal-title":"Pak J Pharm Sci"},{"issue":"6","key":"2378_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/YIC.0b013e32833d18b2","volume":"25","author":"S Farooq","year":"2010","unstructured":"Farooq S, Nazar Z, Akhter J, Irafn M, Subhan F, Ahmed Z, et al. Effect of fasting during Ramadan on serum lithium level and mental state in bipolar affective disorder. Int Clin Psychopharmacol. 2010;25(6):323\u20137.","journal-title":"Int Clin Psychopharmacol"},{"key":"2378_CR19","unstructured":"Nazar Z, Akhtar J, Farooq S, Irfan M, Shaheen R, Ahmad M, et al. Adverse side effects of lithium and fasting (Ramadan). J Postgrad Med Inst. 2011;23(1):7\u201313"},{"issue":"109","key":"2378_CR20","first-page":"2472","volume":"2","author":"G Ayano","year":"2016","unstructured":"Ayano G. Bipolar disorders and valproate: pharmacokinetics, pharmacodynamics and therapeutic effects and indications of valproate: review of articles. Bipolar Disord. 2016;2(109):2472\u20131077.1000109.","journal-title":"Bipolar Disord"},{"key":"2378_CR21","volume-title":"Koda-Kimble and Young\u2019s applied therapeutics: the clinical use of drugs","author":"MA Koda-Kimble","year":"2012","unstructured":"Koda-Kimble MA. Koda-Kimble and Young\u2019s applied therapeutics: the clinical use of drugs: Lippincott Williams & Wilkins; 2012."},{"issue":"2","key":"2378_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0197-0186(00)00013-9","volume":"37","author":"CU Johannessen","year":"2000","unstructured":"Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int. 2000;37(2):103\u201310.","journal-title":"Neurochem Int"},{"key":"2378_CR23","unstructured":"Szende V, Silvia I, Vari C, Titica DM, Daniela-Lucia M, Carmen C, et al. Determination of valproic acid in human plasma by high-performance liquid chromatography with mass spectrometry detection. Acta Med Marisiensis. 2012;58(1)."},{"issue":"2","key":"2378_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/03639040500466155","volume":"32","author":"Y Fujisaki","year":"2006","unstructured":"Fujisaki Y, Tsukune T, Funy\u00fb M, Okumura M, Ukigaya T, Sugibayashi K. Development of sustained-release tablets containing sodium valproate: in vitro and in vivo correlation. Drug Dev Ind Pharm. 2006;32(2):207\u201317.","journal-title":"Drug Dev Ind Pharm"},{"issue":"03","key":"2378_CR25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1055\/s-0037-1613840","volume":"83","author":"MF Buckley","year":"2000","unstructured":"Buckley MF, James JW, Brown DE, Whyte GS, Dean MG, Chesterman CN, et al. A novel approach to the assessment of variations in the human platelet count. Thromb Haemost. 2000;83(03):480\u20134.","journal-title":"Thromb Haemost"},{"issue":"3","key":"2378_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/JCP.0b013e3181db2684","volume":"30","author":"K Vasudev","year":"2010","unstructured":"Vasudev K, Keown P, Gibb I, McAllister-Williams RH. Hematological effects of valproate in psychiatric patients: what are the risk factors? J Clin Psychopharmacol. 2010;30(3):282\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2378_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1176\/appi.ajp.158.1.128","volume":"158","author":"TJ Trannel","year":"2001","unstructured":"Trannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatr. 2001;158(1):128\u201330.","journal-title":"Am J Psychiatr"},{"issue":"2","key":"2378_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4103\/psychiatry.IndianJPsychiatry_158_17","volume":"60","author":"SK Goyal","year":"2018","unstructured":"Goyal SK, Badyal DK. Significant thrombocytopenia with sodium valproate in an adult patient with alcohol dependence. Indian J Psychiatry. 2018;60(2):252\u20133.","journal-title":"Indian J Psychiatry"},{"issue":"1","key":"2378_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-017-0224-6","volume":"18","author":"M Buoli","year":"2018","unstructured":"Buoli M, Serati M, Botturi A, Altamura A. The risk of thrombocytopenia during valproic acid therapy: a critical summary of available clinical data. Drugs R&D. 2018;18(1):1\u20135.","journal-title":"Drugs R&D"},{"key":"2378_CR30","volume-title":"Adherence to long-term therapies: evidence for action","author":"E Sabat\u00e9","year":"2003","unstructured":"Sabat\u00e9 E. Adherence to long-term therapies: evidence for action: World Health Organization; 2003."},{"issue":"12","key":"2378_CR31","first-page":"935","volume":"82","author":"J Connor","year":"2004","unstructured":"Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2004;82(12):935\u20139.","journal-title":"Bull World Health Organ"},{"issue":"3","key":"2378_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2165\/00003495-200262030-00003","volume":"62","author":"DA Sica","year":"2002","unstructured":"Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. Drugs. 2002;62(3):443\u201362.","journal-title":"Drugs."},{"key":"2378_CR33","doi-asserted-by":"crossref","unstructured":"Kendall T, Morriss R, Mayo-Wilson E, Marcus E, Jones S, Group GD. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ. 2014;349.","DOI":"10.1136\/bmj.g5673"},{"issue":"5","key":"2378_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1365-2710.2001.00363.x","volume":"26","author":"E Vermeire","year":"2001","unstructured":"Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331\u201342.","journal-title":"J Clin Pharm Ther"},{"key":"2378_CR35","unstructured":"Ahmed Z, Subhan F, Ahmed S, Rasheed QA, Ahmed S, Shahid M, et al. Development of fixed dose combination tablets of aripiprazole plus divalproex sodium and their simultaneous determination using HPLC-UV. Drug Dev Ind Pharm. 2015(just-accepted):1-39."},{"issue":"8","key":"2378_CR36","first-page":"1668","volume":"38","author":"Z Ahmed","year":"2019","unstructured":"Ahmed Z, Subhan F, Ahmed S, Farooq S, Khan H, Ali A. In vivo evaluation of fixed dose combination tablets of aripiprazole and divalproex sodium; a pilot pharmacokinetic assay. Lat Am J Pharm. 2019;38(8):1668\u201376.","journal-title":"Lat Am J Pharm"},{"key":"2378_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-6395(05)80045-5","volume-title":"Handbook of pharmaceutical analysis by HPLC","author":"S Ahuja","year":"2005","unstructured":"Ahuja S, Dong M. Handbook of pharmaceutical analysis by HPLC: Elsevier; 2005."},{"issue":"9","key":"2378_CR38","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3109\/03639045.2015.1137305","volume":"42","author":"Z Ahmed","year":"2016","unstructured":"Ahmed Z, Subhan F, Ahmed S, Abdur Rasheed Q, Ahmed S, Shahid M, et al. Development of fixed dose combination tablets of aripiprazole plus divalproex sodium and their simultaneous determination using HPLC-UV. Drug Dev Ind Pharm. 2016;42(9):1393\u2013405.","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"2378_CR39","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/13651501.2014.941879","volume":"18","author":"G Eryilmaz","year":"2014","unstructured":"Eryilmaz G, Hizli Sayar G, \u00d6zten E, G\u00fcl IG, Karamustafalio\u011flu O, Yorbik \u00d6. Effect of valproate on the plasma concentrations of aripiprazole in bipolar patients. Int J Psychiatry Clin Pract. 2014;18(4):288\u201392.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"1","key":"2378_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0091270004269870","volume":"45","author":"L Citrome","year":"2005","unstructured":"Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45(1):89\u201393.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2378_CR41","first-page":"14","volume":"3","author":"DJ Muzina","year":"2004","unstructured":"Muzina DJ. Bipolar maintenance: are atypical antipsychotics reallymood stabilizers\u2019? Curr Psychiatry. 2004;3(4):14\u201330.","journal-title":"Curr Psychiatry"},{"issue":"suppl 5","key":"2378_CR42","first-page":"9","volume":"69","author":"TA Ketter","year":"2008","unstructured":"Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry. 2008;69(suppl 5):9\u201315.","journal-title":"J Clin Psychiatry"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02378-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-022-02378-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02378-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T03:39:10Z","timestamp":1666755550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-022-02378-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1208\/s12249-022-02378-7","relation":{},"ISSN":["1530-9932"],"issn-type":[{"type":"electronic","value":"1530-9932"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"6 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments were carried out in accordance with the accepted guidelines approved by the institutional \u201cCommittee for Research Ethics,\u201d Department of Pharmacy, University of Peshawar, Peshawar, Pakistan under license number \u201c<i>UOP\/03\/EC-14\/PHARM, 06, 04, 2014<\/i>.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"232"}}